Jump to the top of the page

Investment Banking

The Quarterly Rx: Q3 2022 U.S. Biopharma Recap

While biopharma markets stabilized in Q3 2022—providing issuers with the most constructive financing environment we have seen year-to-date—macroeconomic issues remain the key headline risk for the near term. Key biopharma indices bounced off multiyear lows, driven by encouraging signs of M&A, meaningful positive clinical news, and broad sector short covering. William Blair's Biopharma team shares perspectives in “The Quarterly Rx: Q3 2022 U.S. Biopharma Recap.

Complete the form below to download your copy of the report.

Delivered to Your Inbox

Stay up-to-date with the latest William Blair news and insights

Subscribe to News Alerts

More News and Insights

  • How Venture Exits to Private Equity Continue to Grow—With Fuel From AI

    Midmarket technology private equity firms and their portfolio companies have become an important exit pathway for VC-backed companies, especially in the AI era.

    Read more

  • William Blair Hires Head of Biopharma Investment Banking, Based in New York

    William Blair announced today the expansion of the firm’s Healthcare team with the addition of Michael Allwin as managing director and head of Biopharma investment banking.

    Read more

  • Preparing Your Life for Liquidity: Post-M&A Success (Beyond the Financials)

    Business owners planning for a liquidity event often focus on the financials. But preparing for their post-transaction lives is just as important—and less tangible considerations should not be ignored.

    Read more
See more insights

Are you sure you want to leave?

Information contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.

For disclosure information, please visit www.williamblair.com/disclosures